While Fulcrum Therapeutics Inc has overperformed by 10.93%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, FULC rose by 105.11%, with highs and lows ranging from $9.88 to $2.32, whereas the simple moving average jumped by 70.42% in the last 200 days.
On July 29, 2025, H.C. Wainwright Upgraded Fulcrum Therapeutics Inc (NASDAQ: FULC) to Buy. A report published by Leerink Partners on May 23, 2025, Upgraded its rating to ‘Outperform’ for FULC. Cantor Fitzgerald also Upgraded FULC shares as ‘Overweight’, setting a target price of $10 on the company’s shares in a report dated May 15, 2025. H.C. Wainwright September 13, 2024d the rating to Neutral on September 13, 2024, and set its price target from $17 to $4. Stifel September 12, 2024d its ‘Buy’ rating to ‘Hold’ for FULC, as published in its report on September 12, 2024. RBC Capital Mkts’s report from September 12, 2024 suggests a price prediction of $4 for FULC shares, giving the stock a ‘Sector Perform’ rating. Leerink Partners also rated the stock as ‘Market Perform’.
Analysis of Fulcrum Therapeutics Inc (FULC)
Further, the quarter-over-quarter decrease in sales is -100.00%, showing a negative trend in the upcoming months.
Fulcrum Therapeutics Inc’s future performance can be predicted by a variety of well-rounded types of analysis and research, with equity being one of the most crucial ones. The goal here is to ensure that your current return on equity of -30.00% is sufficient for you to turn a profit off your investment. Taking into account the quick ratio of the company, currently set at 24.42, you can see that the company can cover any debts it may have, which can easily be seen in the annual report of the company.
For any stock, average volume can be an extremely valuable indicator of volatility, and FULC is registering an average volume of 626.92K. On a monthly basis, the volatility of the stock is set at 6.39%, whereas on a weekly basis, it is put at 6.77%, with a gain of 0.10% over the past seven days. Furthermore, long-term investors anticipate a median target price of $11.64, showing growth from the present price of $9.64, which can serve as yet another indication of whether FULC is worth investing in or should be passed over.
How Do You Analyze Fulcrum Therapeutics Inc Shares?
Besides checking the fundamentals, you should also know how many employees own shares in the company. This is because the values should be in line with investors’ expectations. As such, the current holdings of company stock inside the company are set at 11.36%. This can enable you to see the extent to which executives own the company’s stock. As opposed to executive stock, institutional ownership accounts for 91.02% of the company’s shares, contributing to an indication of company value, since large shareholders may signify strength within the organization.
